News

INOmax Vasodilator Device For Pulmonary Hypertension Approved In Australia And Japan

Dublin, Ireland, based biopharmaceutical company Mallinckrodt plc reports that its INOmax (nitric oxide) vasodilator inhalation device has received regulatory approval in Australia and Japan for treating pulmonary hypertension in conjunction with heart surgery. The Australian Therapeutic Goods Administration (TGA) has approved INOmax for peri- and post-operative pulmonary hypertension…

PHA Celebrates PH Awareness Month with Major Campaign

November is Pulmonary Hypertension Awareness Month and the Pulmonary Hypertension Association (PHA) is planning to launch a new public service campaign called Heart2CurePH that promises to increase understanding of pulmonary hypertension (PH). The worldwide educational campaign will include TV, radio, and place-based and print materials, while anyone on social media can…

Pulmonary Hypertension Gets New Treatment in Helpful Comic Book

The latest comic book in a peer-reviewed series on pulmonary hypertension (PH) has been launched by Medikis, with the collaboration of the Imperial College Healthcare NHS Trust. The comic book, entitled Medikidz Explains Pulmonary Arterial Hypertension, aims to increase knowledge about the life-threatening disease among younger audiences.

GSK’s Application to Expand PAH Drug Volibris’ (ambrisentan) Therapeutic Indication as Combined Treatment Receives Positive CHMP Opinion

GlaxoSmithKline (GSK) recently announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive recommendation for its application to expand the existing therapeutic indication for pulmonary arterial hypertension (PAH) combination treatment Volibris® (ambrisentan) — a selective endothelin type-A receptor antagonist. The therapy is currently approved…

Bariatric Surgery Improves PAH in Patients with Obesity

Obesity is a prevalent comorbidity of pulmonary arterial hypertension (PAH), according to a recent study that examined the presence of metabolic syndrome in patients with PAH. In fact, a large body of research has examined obesity-related PAH. However, patients with both of…

CTEPH Patients in Wales Now Have Option of Using Bayer’s Adempas

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…

PAH Patients Exhibit Skeletal Muscle Abnormalities; Underlying Mechanisms Remain Unknown

In a new study entitled “Signaling pathways underlying skeletal muscle wasting in experimental pulmonary arterial hypertension,” researchers investigated the potential mechanisms underlying patients with pulmonary arterial hypertension characteristic skeletal muscle abnormalities. The researchers identified that muscle loss is prompted by accumulation of dysfunctional mitochondrias and ineffective removal of damaged…

Prostacyclin May Treat Sarcoidosis-Associated Pulmonary Hypertension

A recent article suggests prostacyclin therapy, which is used for the treatment of pulmonary arterial hypertension (PAH), may also be useful for treating sarcoidosis-associated pulmonary hypertension (SAPH). PAH refers to high blood pressure of the lungs. The condition can occur as a result of several different diseases, including sarcoidosis; a disease…